Clinical Trial Search

Primary: Geometric Mean Titers (GMTs) of Anti-Hepatitis B Before and After 3 Dose Primary Vaccination With Either DTaP-IPV-Hep B-PRP~T Batch A, B, or C, or Infanrix Hexa™ — 4.02…

Primary: Young Mania Rating Scale (YMRS) — 24.8; 21.6 Scores on a scale

Primary: Number of Subjects Reporting Solicited Local Symptoms — 95; 82; 52 Participants

Primary: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) — 80.1; 89.3…

Primary: Progression-free Survival — 6.2; 3.3 Months — p=<0.0001

Primary: Percent Change in Psoriasis Area and Severity Index (PASI) From Week 12 to Week 24 — 17.02; 0.86 percent change

Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) — -0.30; -0.67; -0.70; -0.84 Percent — p=0.0002

Primary: Number of Participants With Seroprotection After Primary Series Vaccination With DTaP-IPV-Hep B-PRT~T or CombAct Hib™ + Engerix B™ + Oral Polio Vaccine (OPV) — 176; 185…

Primary: Hemoglobin Concentration at 6 Months — 117; 113 g/L

Primary: Major Bleeding — 11.2; 8.4 Percent probability

Primary: Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants — 0.02; -0.68; -0.72; -0.82…

Primary: Progression Free Survival (PFS) — 14.7; 15.4; 17.3 months — p=0.458

Primary: Percentage of Participants Achieving SVR12 — 51.0; 72.6 percentage of participants — p=< 0.001

Primary: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12 — -10.40; -7.34 mm Hg — p=0.0010

Primary: McMaster Gross Motor Function (GMFM 88) — -0.002; -0.12 units on a scale — p=0.95